Pharmaceutical Executive-06-01-2001

June 01, 2001

FDA district offices may conduct site investigations to establish baseline information for sampling programs and tracking systems.

June 01, 2001

The world's steadily growing oncology market features key elements that are common to all competitors in the category: a highly respected sales forces, sophisticated and deeply involved patients and caregivers, clinically entrepreneurial physicians, and a dynamic global regulatory environment. Yet the uncharted territory of cancer breakthroughs demands that pharma marketers temper a strategy of progressive risk with caution.

June 01, 2001

Driven by the quest for innovation, the intensity of competition, and the pressure to create megabrands and megamergers, pharmaceutical executives are exploring an influential force still untapped by most marketing and communication departments-the power of emotion.

June 01, 2001

MMRF is run more like a Fortune 500 company than a foundation. It is defined by a mission, short- and long-term goals, a business plan for growth, a board of directors, and a scientific advisory board. The mix works. Under Giusti's stewardship, MMRF has exceeded fundraising expectations while remaining a model of efficiency-less than 5 percent of capital raised has been spent on administrative costs.

June 01, 2001

Cancer makes neurology seem almost simple by comparison. Cancers come in a nearly infinite variety. Yet their mechanisms, scientists now surmise, may reside in the same place-deep inside the cell. DNA, genes, and cellular proteins play key roles in both disease areas.

June 01, 2001

Hosbjor, Norway-Away from the media glare in South Africa, a three-day workshop sponsored by the World Health and World Trade organizations sought to improve access to life-saving medicines in developing countries. Also backed by the Norwegian Foreign Ministry and the Global Health Council, the workshop brought together 80 experts from 23 countries and highlighted the use of differential pricing as a means of improving access.

June 01, 2001

Driven by the quest for innovation, the intensity of competition, and the pressure to create megabrands and megamergers, pharmaceutical executives are exploring an influential force still untapped by most marketing and communication departments-the power of emotion.

June 01, 2001

Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.

June 01, 2001

The founder of five biotech companies rarely pauses, even to rest. "I can do a lot of work when the rest of my family is sleeping," he reports. "Early in the morning or late at night, there are no phones, so I needn't divert my attention." His affable tone seems contrary to the relentless drive needed to support a lifelong pursuit of excellence, but his achievements speak for themselves.

June 01, 2001

The founder of five biotech companies rarely pauses, even to rest. "I can do a lot of work when the rest of my family is sleeping," he reports. "Early in the morning or late at night, there are no phones, so I needn't divert my attention." His affable tone seems contrary to the relentless drive needed to support a lifelong pursuit of excellence, but his achievements speak for themselves.

June 01, 2001

Berlin, Germany-Putting the US market at the heart of its bid to maintain double-digit growth, last month Schering began to relocate its therapeutics headquarters to an existing facility in Montville, New Jersey.

June 01, 2001

Schering’s commitment to biotechnology in the early 1990s was a landmark decision for the company, says Dr. Guiseppe Vita, who is stepping down as chairman of the Berlin-based company. The result of that commitment was Betaferon (interferon beta-Ib), one of the first biotech products on the market in Germany. It is now Schering’s biggest product and one of the top ten best selling biotech therapies in the world.

June 01, 2001

Buckinghamshire, UK-The pharma industry may be countercyclical, but it’s not immune to market trends. Nycomed Amersham recently postponed a partial US stock flotation of its life sciences company, ABBiotech, because of market weakness.

June 01, 2001

I intended to write an entirely different column this month. Something like, What the Bush administration has done for you-the pharmaceutical industry-lately. Such as making it harder to do stem-cell research and pursuing an investigation into antigeneric activities. But something else happened. My father died. Now I have no room left in my mind or heart for other matters.